Merck and Pfizer secure US FDA approval for Bavencio to treat skin cancer
Merck ’s biopharmaceutical business EMD Serono and Pfizer have obtained the US Food and Drug Administration’s (FDA) approval for a 20mg/mL Bavencio (avelumab) injection to treat patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggress…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Merck | Merkel Cell Carcinoma | Pfizer | Pharmaceuticals | Skin | Skin Cancer